New pill shows promise against rare cancer in early trial
NCT ID NCT07032285
First seen Apr 09, 2026 · Last updated May 11, 2026 · Updated 7 times
Summary
This study tests a new oral drug called cirtuvivint for people with advanced soft-tissue sarcoma that has not responded to prior treatment. About 25 participants in Spain will take the drug to see if it can stop or slow tumor growth for at least 3 months. The drug is still experimental and not yet approved.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA (STS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical Oncology Department, HU Fundación Jimenez Diaz
RECRUITINGMadrid, Madrid, 28040, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.